Those gliomas in CRGRS high-risk group would harbor more immune cell infiltration, express more immunotherapy targets (including PD-1, PD-L1, CTLA4, and B7H3), and therefore could potentially present a better response to immunotherapy. Here, CD276 is linked to central nervous system cancer.